Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...

NICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England and Wales, three months after rejecting it on cost grounds, via the ...

Novartis has reported a 28.5% reduced risk of breast cancer recurrence in an updated analysis from the Phase III NATALEE trial of Kisqali (ribociclib), when combined with endocrine therapy.

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

The Biomedical Sciences Poster Service Center is an in-house service center that offers poster printing services to the UAB community and the public at minimal costs. Business hours are 8 a.m.- 4:30 p ...

The use of PowerPoint to create posters is the weapon of choice for smart researchers. Choose from this selection of horizontally and vertically oriented PowerPoint shows with branded backgrounds, or ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

How to make a poster. You will find posters everywhere. They’re on the side of buildings, in shop windows, on the side of roads, on bus stops and even on buses! Posters are mainly used to ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...